Control Of India's Concord Sold By Mylan Arm To Investors
This article was originally published in PharmAsia News
Executive Summary
India's Concord Biotech has lost its major stakeholder, U.S.-based Mylan Laboratories and its subsidiary, Matrix Laboratories